The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News